Proteomic profiling of proteins associated with lymph node metastasis in colorectal cancer

Journal of Cellular Biochemistry

Volumn 110, Issue 6, 2010, Pages 1512-1519

  Ma, Yiming ^a   Zhao, Mei ^a   Zhong, Jialing ^a   Shi, Lan ^a   Luo, Qing ^a   Liu, Jian ^a   Wang, Jia ^a   Yuan, Xinghua ^a   Huang, Changzhi ^a  

^a CANCER HOSPITAL   (China)

Author keywords

Colorectal cancer; Lymph node metastasis; Proteomics; UCH L1

Indexed keywords

CATHEPSIN D; FERRITIN; UBIQUITIN THIOLESTERASE;

ARTICLE; CLINICAL ARTICLE; COLON MUCOSA; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ADULT; AGED; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL MOVEMENT; COLORECTAL NEOPLASMS; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTESTINAL MUCOSA; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PROTEOME; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TISSUE ARRAY ANALYSIS; TRANSFECTION; TUMOR MARKERS, BIOLOGICAL; UBIQUITIN THIOLESTERASE;

EID: 77955504084     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.22726     Document Type: Article

References (43)

1. Alfonso P, Nunez A, Madoz-Furpide J, Lombardia L, Sanchez L, Casal JI. 2005. Proteomic expression analysis of colorectal cancer by two-dimensional differential gel electrophoresis. Proteomics 10:2602-2611.
2. Ames BN, Shigenaga MK, Hagen TM. 1993. Oxidants, antioxidants, and degenerative diseases of aging. Proc Natl Acad Sci USA 90:7915-7922.
3. Baxter NN, Virnig DJ, Rothenberger DA, Morris AM, Jessurum J, Virnig BA. 2005. Lymph node evaluation in colorectal cancer patients: A population-based study. J Natl Cancer Inst 97:219-225.
4. Betarber R, Sherer TB, Greenamyre JT. 2005. Ubiquitin-proteasome system and Parkinson's diseases. Neurochem Int 51:105-111.
5. Bheda A, Yue W, Gullapalli A, Whitehurst C, Liu R, Pagano JS, Shackelford J. 2009. Positive reciprocal regulation of ubiquitin C-terminal hydrolase L1 and beta-catenin/TCF signaling. PLoS ONE 4:e5955.
6. Bilello JP, Cable EE, Isom HC. 2003. Expression of E-cadherin and other paracellular junction genes is decreased in iron-loaded hepatocytes. Am J Pathol 162:1323-1338.
7. Birchmeier W, Weidner KM, Behrens J. 1993. Molecular mechanisms leading to loss of differentiation and gain of invasiveness in epithelial cells. J Cell Sci Suppl 17:159-164.
8. Boult J, Roberts K, Brookes MJ, Hughes S, Bury JP, Cross SS, Anderson GH, Spychal R, Lqbal T, Tselepis C. 2008. Overexpression of cellular iron import proteins is associated with malignant progression of esophageal adenocarcinoma. Clin Cancer Res 14:379-387. (Pubitemid 351226104)
9. Brookes MJ, Hughes S, Turner FE, Reynolds G, Sharma N, Ismail T, Berx G, McKie AT, Hotchin N, Anderson GJ, Iqbal T, Tselepis C. 2006. Modulation of iron transport proteins in human colorectal carcinogenesis. Gut 55:1449-1460.
10. Chang GJ, Rodriguez-Bigas MA, Skibber JM, Moyer VA. 2007. Lymph node evaluation and survival after curative resection of colon cancer: Systematic review. J Natl Cancer Inst 99:433-441.
11. Chen X, Yang G, Ding WY, Bondoc F, Curtis SK, Yang CS. 1999. An esophagogastroduodenal anastomosis model for esophageal adenocarcinogenesis in rats and enhancement by iron overload. Carcinogenesis 20: 1801-1808.
12. Cohen C, Shulman G, Budgeon LR. 1984. Immunohistochemical ferritin in testicular seminoma. Cancer 54:2190-2194.
13. Derwinger K, Carlsson G, Gustavsson B. 2008. A study of lymph node ratio as a prognostic marker in colon cancer. Eur J Surg Oncol 34:771-775.
14. Foekens JA, Look MP, Bolt-de Vries J, Meijer-van Gerder ME, van Putten WL, Klijn JG. 1999. Cathepsin-D in primary breast cancer: Prognostic evaluation involving 2810 patients. Br J Cancer 79:300-307.
15. Friedman DB, Hill S, Keller JW, Merchant NB, Levy SE, Coffey RJ, Caprioli RM. 2004. Proteome analysis of human colon cancer by two-dimensional difference gel electrophoresis and mass spectrometry. Proteomics 3:793-811.
16. Fukutomi S, Seki N, Koda K, Miyazaki M. 2007. Identification of methylation-silenced genes in colorectal cancer cell lines: Genomic screening using oligonucleotide arrays. Scand J Gastroenterol 42:1486-1494.
17. Giusti L, Iacconi P, Ciregia F. 2008. Fine-needle aspiration of thyroid nodules: Proteomic analysis to identify cancer biomarkers. J Proteome Res 7:4079-4088.
18. Hanash S. 2003. Disease proteomics. Nature 422:226-232.
19. Hibi K, Westra WH, Borges M, Goodman S, Sidransky D, Jen J. 1999. PGP9.5 as a candidate tumor marker for non-small-cell lung cancer. Am J Pathol 155:711-715.
20. Kanber Y, Demirbag NR, Sam AD, Aydin N. 2002. Cathepsin D expression in colorectal adenocarcinomas and adenomas. Int J Biol Markers 17:165-168.
21. Kavallaris M, Marshall GM. 2005. Proteomics and disease: Opportunities and challenges. Med J Aust 182:575-579.
22. Kim HJ, Kim YM, Lim S, Nam YK, Jeong J, Kim H-J, Lee K-J. 2009. Ubiquitin C-terminal hydrolase-L1 is a key regulator of tumor cell invasion and metastasis. Oncogene 28:117-127.
23. Leiblich A, Cross SS, Catto JW, Pesce G, Hamdy FC, Rehman I. 2007. Human prostate cancer cells express neuroendocrine cell markers PGP 9.5 and chromogranin A. Prostate 67:1761-1769.
24. Liu Y, Fallon L, Lashuel HA, Liu Z, Lansbury PT, Jr. 2002. The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility. Cell 111:209-218.
25. Mandelker DL, Yamashita K, Tokumaru Y, Minori K, Howard DL, Tanaka Y, Carvalho AL, Jiang WW, Park HL, Kim MS, Osada M, Mori M, Sidransky D. 2005. PGP9.5 promoter methylation is an independent prognostic factor for esophageal squamous cell carcinoma. Cancer Res 65:4963-4968.
26. Mizukami H, Shirahata A, Goto T, Sakata M, Saito M, Ishibashi K, Kigawa G, Nemoto H, Sanada Y, Hibi K. 2008. PGP9.5 methylation as a marker for metastatic colotectal cancer. Anticancer Res 28:2697-2700.
27. Mueller MM, Fusenig NE. 2004. Friends or foes-bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 4:839-849.
28. Newcomb PA, Norfleet RG, Storer BE, Surawicz TS, Marcus PM. 1992. Screening sigmoidoscopy and colorectal cancer mortality. J Natl Cancer Inst 84:1572-1575.
29. Oh-e H, Tanaka S, Kitadai Y, Shimamoto F. 2001. Cathepsin D expression as a possible predictor of lymph node metastasis in submucosal colorectal cancer. Eur J Cancer 37:180-188. (Pubitemid 32144694)
30. Okochi-Takada E, Nakazawa K, Wakabayashi M, Mori A, Ichimura S, Yasugi T, Ushijima T. 2006. Silencing of the UCHL1 gene in human colorectal and ovarian cancers. Int J Cancer 119:1338-1344.
31. Ott V, Guenther K, Steinert R, Tortola S, Borisch B, Schlegel W, Reymond MA. 2001. Accuracy of two-dimensional electrophoresis for target discovery in human colorectal cancer. Pharmacogenomics J 1:142-151.
32. Ravdin PM. 1993. Evaluation of Cathepsin D as a prognostic factor in breast cancer. Breast Cancer Res Treat 24:219-226.
33. Schofield JN, Day IN, Thompson RJ, Edwards YH. 1995. PGP9.5, a ubiquitin C-terminal hydrolase; pattern of mRNA and protein expression during neural development in the mouse. Brain Res Dev Brain Res 85:229-238.
34. Scorilas A, Yotis J, Pateras C, Trangas T, Talieri M. 1999. Predictive value of c-erbB-2 and Cathepsin-D for Greek breast cancer patients using univariate and multivariate analysis. Clin Cancer Res 5:815-821.
35. Selby JV, Friedman GD, Quesenberry CP, Jr., Weiss NS. 1992. A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. N Engl J Med 326:653-657.
36. Takase T, Hibi K, Yamazaki T, Nakayama H, Taguchi M, Kasai YX, Ito K, Akiyama S, Nagasaka T, Nakao A. 2003. PGP9.5 overexpression in esophageal squamous cell carcinoma. Hepatogastroenterology 50:1278-1280.
37. Tezel E, Hibi K, Nagasaka T, Nakao A. 2000. PGP9.5 as a prognostic factor in pancreatic cancer. Clin Cancer Res 6:4764-4767.
38. Vet JA, van Moorselaar RJ, Debruyne FM, Schalken JA. 1997. Differential expression of ferritin heavy chain in a rat transitional cell carcinoma progression model. Biochim Biophys Acta 1360:39-44.
39. Weinstein RE, Bond BH, Silberberg BK. 1982. Tissue ferritin concentration in carcinoma of the breast. Cancer 50:2406-2409.
40. Westley BR, May FE. 1996. Cathepsin D and breast cancer. Eur J Cancer 32A:15-24.
41. Wilkinson KD, Lee KM, Deshpande S, Duerksen-Hughes P, Boss JM, Pohl J. 1989. The neuron-specific protein PGP 9.5 is a ubiqutin carboxyl-terminal hydrolase. Science 246:670-673.
42. Wu CG, Groenink M, Bosma A, Reitsma PH, van Deventer SJ, Chamuleau RA. 1997. Rat ferritin-H: CDNA cloning, differential expression and localization during hepatocarcinogenesis. Carcinogenesis 18:47-52.
43. Yamazaki T, Hibi K, Takase T, Tezel E, Nakayama H, Dasai Y, Ito K, Akiyama S, Nagasaka T, Nakao A. 2002. PGP9.5 as a marker for invasive colorectal cancer. Clin Cancer Res 8:192-195.